While the Treatment for Adolescents With Depression Study (TADS) involved only Prozac as a study drug, there were plenty of other companies invested in countering the FDA’s 2004 Warning about suicidality in adolescents on SSRIs: [patent life of the antidepressants] Now looking at the Financial Disclosures from the four key TADS articles that I mentioned […]
ICD-10-CM Delay Removes Excuse for Rushing DSM 5 Into Premature Publication DSM-5 in Distress: Psychology Today by Allen Frances, M.D. February 22, 2012 Until yesterday, there were only two reasons to stick with the projected date of DSM 5 publication [May 2013]: [1] the need to coordinate DSM 5 with ICD-10-CM coding, which was scheduled […]
This post is a continuation of the last one [significant I…] using the same reference articles [A1-A5, B1-B3, & C1-C2]… The question of suicidality as an adverse effect from SSRIs in adolescents and children is no small matter. I don’t think anyone is saying never use these drugs in youth [at least I’m not]. The […]
There has been no recent issue as hotly contested as the question of whether the SSRIs can induce suicidal thinking, particularly in youth. In 2004, the FDA added a black-box warning to the SSRIs, resulting in a fall in prescribing, and a polarized literature on this topic that lives on. Recently, the focus has been […]
Yesterday, I got an email asking for the source of something I posted recently. It was from a pretty incriminating document from Forest Laboratories entitled Lexapro: FY04 Marketing Plan [available here]. I originally got the reference from one of Paul Thacker’s POGO articles [You’re Fired: Forest Lab’s CEO May Be Banned from Federal Healthcare]. The […]
One of the most admirable traits in another person is humility. We’re drawn to people who don’t have to be right all the time, who have an accurate view of themselves, who can acknowledge their own foibles and even misdeeds. And yet for all the respect we might feel for the humble man, achieving a […]
About-turn on treatment of the young Sydney Morning Herald by Amy Corderoy February 20, 2012 Professor McGorry has been part of a team researching pre- and early-psychosis, and his work in the latter helped secure a massive $222.4 million Commonwealth funding injection for Early Psychosis Prevention and Intervention Centres across Australia. They have found symptoms […]
The most amazing thing about humans is that we do the same things over and over, often uncolored by previous experiences. This idea of treating Major Depressive Disorder with some kind of Medication Algorithm directed by a computer program is one of those things that has trouble dying [at least in Dallas]. Notice [3] and […]
The last case of Friday’s clinic day was a fourteen year old boy who weighed in the high two hundreds, but didn’t look obese, more like a lineman for the Packers. He was soft-spoken and shy at first glance. He was on probation after being caught with Marijuana at school last year, and was referred […]
"He [Ian Hickie] also noted that the Lancet had recently published another review, by prominent US psychiatrist David Kupfer, which drew similar conclusions on the efficacy and tolerability of agomelatine. However this article had not triggered the same dissent, despite describing the drug as a “promising alternative” for certain patients." [see if you can’t do […]